Form 4: Guardant Health CPO's Routine Stock Transactions

Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Terilyn J. Monroe, Chief People Officer of Guardant Health, Inc. [GH], reported transactions on January 15, 2026.
• Acquired 17,379 shares of Common Stock at a price of $0 through the vesting of Restricted Stock Units (RSUs).
• Disposed of 8,808 shares of Common Stock at a price of $111.98 to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, beneficial ownership stands at 29,561 shares of Common Stock.
• The RSUs were granted on February 26, 2024, with 33% vesting on January 15, 2025, and the remaining 67% vesting annually over the subsequent two years.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a disposition of shares, it's a routine, pre-planned event for tax purposes following RSU vesting, indicating continued executive equity participation rather than a discretionary sale based on new information.

Positives

• The vesting of 17,379 Restricted Stock Units indicates continued equity participation and alignment of management interests with shareholders.
• The transaction is a routine event, often pre-scheduled, reflecting a standard compensation structure.

Negatives

• The disposition of 8,808 shares, even for tax purposes, reduces the direct beneficial ownership of the Chief People Officer.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the pre-defined vesting schedule for the remaining Restricted Stock Units.

Industry Context

This filing represents a routine insider transaction common across all industries for executives receiving equity-based compensation. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as part of executive compensation is a standard practice across the biotechnology and healthcare technology sectors, aligning executive incentives with long-term shareholder value.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is a common and expected event for executives receiving such awards, consistent with practices at comparable companies like Illumina or Exact Sciences.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-scheduled insider transaction for compensation and tax purposes, not indicative of a change in company fundamentals or management's discretionary view of the stock.
• Employees: Reflects standard executive compensation practices, which can influence broader employee compensation strategies.

Next Steps

• Remaining 67% of the Restricted Stock Units will vest annually over the next two years, following the initial 33% vesting on January 15, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled insider transaction involving the vesting of Restricted Stock Units and the subsequent sale of shares to cover tax obligations. Such events are common for executives receiving equity compensation and do not typically signal a change in the company's fundamental outlook or warrant a shift in investment thesis. Therefore, a 'hold' recommendation is appropriate as no new material information affecting the company's valuation or prospects has been disclosed.

Keywords

Guardant Health, GH, Form 4, Insider Transaction, Restricted Stock Units, RSU, Beneficial Ownership, Stock Vesting, Tax Withholding